New study suggests J&J recipients should get booster shot to protect against Delta variant


A free daily digest of the biggest news stories of the day - and the best features from our website
Thank you for signing up to TheWeek. You will receive a verification email shortly.
There was a problem. Please refresh the page and try again.
Recipients of the one-shot Johnson & Johnson COVID-19 vaccine may need to get a second dose to protect against the Delta and Lambda coronavirus variants because its less effective against them, a new study suggests, per The New York Times.
"The message that we wanted to give was not that people shouldn't get the J&J vaccine, but we hope that in the future, it will be boosted with either one dose of J&J or a booster with [the Pfizer and Moderna COVID-19 vaccines]," Nathaniel Landau, a virologist at New York University's Grossman School of Medicine who led the study, told the Times.
The study, which has not been peer reviewed, involvded Landau and his team looking at blood samples taken from 17 people who had received both doses of the Pfizer and Moderna vaccines and 10 people with one dose of J&J. The J&J vaccine started out with a lower efficacy rate, which dropped more sharply against the variants, the Times reports. However, because the study was based on lab experiements, the Food and Drug Administration is unlikely to change its single-dose recommendation because of it, the Times notes. Further, seperate small studies published by researchers affialiated with J&J found that the vaccine's protection strengthened over time. Read more at The New York Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
Sign up to our 10 Things You Need to Know Today newsletter
A free daily digest of the biggest news stories of the day - and the best features from our website
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Why New York City was caught off guard by flash flooding
Talking Point Is climate change moving too fast or are city leaders dragging their feet?
By Theara Coleman Published
-
Today's political cartoons - October 2, 2023
Monday's cartoons - Biden's EV plan, the Senate dress code, and more
By The Week Staff Published
-
What is Rep. Matt Gaetz's endgame?
Today's Big Question The MAGA congressman loves to sow chaos, but there might be more to his latest moves than just disruption.
By Rafi Schwartz Published
-
How do we calculate mass deaths?
The Explainer Recent revisions to 9/11, Libyan flood and Covid-19 death tolls raise questions over estimates
By Harriet Marsden, The Week UK Published
-
You can now get a new Covid booster shot. Should you?
Unless you are old or otherwise at high risk, it isn't a 'slam dunk'
By Peter Weber Published
-
FDA to re-evaluate effectiveness of common nasal congestion ingredient
Speed Read
By Justin Klawans Published
-
A flesh-eating bacteria is growing in numbers due to climate change
Speed Read
By Devika Rao Published
-
CDC recommends new RSV vaccine for infants under 8 months
Speed Read
By Devika Rao Published
-
U.S. health agency advises easing federal marijuana restrictions
Speed Read
By Peter Weber Published
-
Medicare drug price negotiations start with 1st 10 drugs, pharmaceutical industry lawsuits
Speed Read
By Peter Weber Published
-
Is it time to mask up again?
Today's Big Question A rise in Covid-19 cases brings back the possibility of mask mandates
By Joel Mathis Published